Web Results

www.cancer.ca/.../cancer-type/prostate/prognosis-and-survival/?region=on

PSA doubling time measures the time it takes the PSA level to double. For example, a PSA doubling time of 3 years means that, on average, the PSA level doubles every 3 years. PSA doubling time can help doctors find out if a prostate cancer is aggressive, which means it is more likely to grow quickly and spread.

prostatecancerfree.org/pca-commentary-145-psa-psa-dynamics-and-advances-in...

‘Prostate-specific antigen doubling time of < 7.5 months and Gleason score are independent predictors of metastases-free survival…” They reported that compared to Gleason score of 6, men with Gleason score 7 carried a 1.75 times greater risk and Gleason score 8 – 10 a 3.44 times greater risk of developing metastatic disease.

www.practiceupdate.com/content/psa-doubling-time-and-absolute-psa-predict...

PSA Doubling Time and Absolute PSA Predict Metastasis-Free Survival in Men With Biochemically Recurrent Prostate Cancer After Radical Prostatectomy Clin Genitourin Cancer 2019 Dec 01;17(6)470-475.e1, MC Markowski, Y Chen, Z Feng, J Cullen, BJ Trock, D Suzman, ES Antonarakis, CJ Paller, I Rosner, M Han, PC Walsh, AW Partin, M Eisenberger From ...

ro-journal.biomedcentral.com/articles/10.1186/s13014-017-0837-5

A prognostic impact of the PSA doubling time was also reported in another study, demonstrating a 10-year disease-specific survival rate of 30% for patients with a PSA failure and a PSA doubling time ≤6 months vs. 67% and 98% for those with PSA failure and doubling time >6-10 months and >10 months .

bjui-journals.onlinelibrary.wiley.com/doi/pdf/10.1111/bju.13856

survival, but not time to metastases [7]. Third, a post hoc analysis of a clinical trial examining the efficacy of denosumab in men with M0 CRPC at high risk of metastases (PSA ≥8 ng/mL or PSADT ≤10 months) showed that a shorter PSADT was associated with shorter bone metastasis-free survival and time to bone metastasis [8]. Finally, an

www.sciencedirect.com/science/article/abs/pii/S155876731630252X

In univariable analysis, older age, more remote year of mCRPC, nonblack race, greater number of bone metastasis, higher prostate-specific antigen (PSA) levels, shorter PSA doubling time, and faster PSA velocity at mCRPC diagnosis were significantly associated with shorter overall survival (all P < .05).

www.hopkinsmedicine.org/brady-urology-institute/specialties/conditions-and...

If your PSA doubled in less than three months, your risk of dying from prostate cancer is much higher than that of a patient whose PSA doubling time was more than a year. If your PSA appeared on a blood test within three years after surgery, you are at a higher risk than a patient whose PSA returns within five years.

www.renalandurologynews.com/home/news/urology/prostate-cancer/proximal-psa...

PSA Doubling Time Predicts Metastasis, Mortality Risks in CRPC PSA in Midlife Can Predict Later Risk of Prostate Cancer Mets The median metastasis-free survival (MFS) times differed significantly ...

www.cancer.org/cancer/prostate-cancer/treating/psa-levels-after-treatment

Some evidence shows that faster-rising PSA levels may be a sign of cancer. Men who have a PSA level that doubles within a 3-month period tend to have a worse prognosis (outlook) compared to men whose PSA level does not double. This is also known as PSA doubling time. After radiation therapy

www.sciencedirect.com/science/article/pii/S0959804915010345

Last but not least, data on PSA at BCR, PSA doubling time, family history of aggressive PCa, tumour volume and micro-metastases in lymph nodes were not available for all patients included in our studies. Future well-designed studies could improve our model in terms of predictive power adding these variables. 5. Conclusions